These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 29782049)

  • 1. Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial.
    Dodick DW; Tepper SJ; Friedman DI; Gelfand AA; Kellerman DJ; Schmidt PC
    Headache; 2018 Jul; 58(7):986-992. PubMed ID: 29782049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches.
    Tepper SJ; Dodick DW; Schmidt PC; Kellerman DJ
    Headache; 2019 Apr; 59(4):509-517. PubMed ID: 30698272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine.
    Spierings EL; Brandes JL; Kudrow DB; Weintraub J; Schmidt PC; Kellerman DJ; Tepper SJ
    Cephalalgia; 2018 Feb; 38(2):215-224. PubMed ID: 29022755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
    Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
    Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
    Ailani J; McAllister P; Winner PK; Chakhava G; Krog Josiassen M; Lindsten A; Sperling B; Ettrup A; Cady R
    BMC Neurol; 2022 Jun; 22(1):205. PubMed ID: 35659622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea.
    Schulman EA
    Headache; 2012 Feb; 52(2):204-12. PubMed ID: 22229837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study.
    Gawel M; Aschoff J; May A; Charlesworth BR;
    Headache; 2005 Jan; 45(1):7-16. PubMed ID: 15663607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study.
    Munjal S; Singh P; Reed ML; Fanning K; Schwedt TJ; Dodick DW; Buse DC; Lipton RB
    Headache; 2020 Feb; 60(2):416-429. PubMed ID: 31837007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of Acute Treatment of Migraine Trial Results With the New FDA Endpoints: Design Implications for Future Trials.
    Hindiyeh NA; Kellerman DJ; Schmidt PC
    Headache; 2019 May; 59(5):819-824. PubMed ID: 30953576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine-Associated Nausea and Prior Triptan Use on Efficacy.
    Lipton RB; Schmidt P; Diener HC
    Headache; 2017 May; 57(5):756-765. PubMed ID: 28386945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubrogepant for the Treatment of Migraine.
    Dodick DW; Lipton RB; Ailani J; Lu K; Finnegan M; Trugman JM; Szegedi A
    N Engl J Med; 2019 Dec; 381(23):2230-2241. PubMed ID: 31800988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of zolmitriptan nasal spray for the treatment of acute migraine in adolescents: Results of a randomized, double-blind, multi-center, parallel-group study (TEENZ).
    Winner P; Farkas V; Štillová H; Woodruff B; Liss C; Lillieborg S; Raines S;
    Headache; 2016 Jul; 56(7):1107-19. PubMed ID: 27329280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine.
    Tuchman M; Hee A; Emeribe U; Silberstein S
    CNS Drugs; 2006; 20(12):1019-26. PubMed ID: 17140280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, controlled trial of telcagepant for the acute treatment of migraine.
    Connor KM; Shapiro RE; Diener HC; Lucas S; Kost J; Fan X; Fei K; Assaid C; Lines C; Ho TW
    Neurology; 2009 Sep; 73(12):970-7. PubMed ID: 19770473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.
    Ho TW; Ferrari MD; Dodick DW; Galet V; Kost J; Fan X; Leibensperger H; Froman S; Assaid C; Lines C; Koppen H; Winner PK
    Lancet; 2008 Dec; 372(9656):2115-23. PubMed ID: 19036425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis.
    Cady R
    Headache; 2002 Jan; 42 Suppl 1():26-31. PubMed ID: 11966861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies.
    Ashina M; Vasudeva R; Jin L; Lombard L; Gray E; Doty EG; Yunes-Medina L; Kinchen KS; Tassorelli C
    Headache; 2019 Nov; 59(10):1788-1801. PubMed ID: 31529622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study.
    Landy S; Munjal S; Brand-Schieber E; Rapoport AM
    J Headache Pain; 2018 Aug; 19(1):70. PubMed ID: 30112725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IM ketorolac vs diclofenac potassium powder for oral solution for the acute treatment of severe migraine: a randomized controlled trial.
    Engel ER; Cheng J
    Neurol Sci; 2020 Mar; 41(3):537-542. PubMed ID: 31833000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Part II: clinical efficacy and tolerability of zolmitriptan orally disintegrating tablet in the acute treatment of migraine.
    Loder EW; Dowson AJ; Spierings EL
    Curr Med Res Opin; 2005; 21 Suppl 3():S8-12. PubMed ID: 16083518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.